

Global Genetic Testing for Cancer Risk Market 2023 by Company, Regions, Type and Application, Forecast to 2029

https://marketpublishers.com/r/G1A97A8C4A17EN.html

Date: March 2023

Pages: 111

Price: US\$ 3,480.00 (Single User License)

ID: G1A97A8C4A17EN

Abstracts

According to our (Global Info Research) latest study, the global Genetic Testing for Cancer Risk market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Cancer risk genetic testing looks for changes in someone's genes. Genetic changes can cause some cancers. Some cancers can run in families.

This report is a detailed and comprehensive analysis for global Genetic Testing for Cancer Risk market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Genetic Testing for Cancer Risk market size and forecasts, in consumption value (\$ Million), 2018-2029

Global Genetic Testing for Cancer Risk market size and forecasts by region and country, in consumption value (\$ Million), 2018-2029



Global Genetic Testing for Cancer Risk market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2018-2029

Global Genetic Testing for Cancer Risk market shares of main players, in revenue (\$ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Genetic Testing for Cancer Risk

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Genetic Testing for Cancer Risk market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Myriad Genetics, Inc., Invitae Corporation, Illumina, Inc., Natera, Inc. and Laboratory Corporation of America Holdings, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Genetic Testing for Cancer Risk market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Breast Cancer Risk Genetic Testing

Stomach Cancer Risk Gene Testing



Rectal Cancer Risk Genetic Testing	
Others	
Market segment by Application	
Hospital	
Clinic	
Laboratory	
Market segment by players, this report cover	rs
Myriad Genetics, Inc.	
Invitae Corporation	
Illumina, Inc.	
Natera, Inc.	
Laboratory Corporation of America H	loldings
F. Hoffmann-La Roche Ltd	
Quest Diagnostics Incorporated	
CooperSurgical, Inc.	
Agilent Technologies, Inc.	
Thermo Fisher Scientific, Inc.	
Twist Bioscience	
Sophia Genetics	



	Fulgent Genetic, Inc.
	Medgenome
	CENTOGENE
	CeGaT
	LifeLabs Genetics
	Ambry Genetics
Market	segment by regions, regional analysis covers
	North America (United States, Canada, and Mexico)
	Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
	Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
	South America (Brazil, Argentina and Rest of South America)
	Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The co	ntent of the study subjects, includes a total of 13 chapters:
•	er 1, to describe Genetic Testing for Cancer Risk product scope, market overview estimation caveats and base year.
•	er 2, to profile the top players of Genetic Testing for Cancer Risk, with revenue, margin and global market share of Genetic Testing for Cancer Risk from 2018 to

Global Genetic Testing for Cancer Risk Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Chapter 3, the Genetic Testing for Cancer Risk competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.



Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Genetic Testing for Cancer Risk market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War

Chapter 12, the key raw materials and key suppliers, and industry chain of Genetic Testing for Cancer Risk.

Chapter 13, to describe Genetic Testing for Cancer Risk research findings and conclusion.



Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Genetic Testing for Cancer Risk
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Genetic Testing for Cancer Risk by Type
- 1.3.1 Overview: Global Genetic Testing for Cancer Risk Market Size by Type: 2018 Versus 2022 Versus 2029
- 1.3.2 Global Genetic Testing for Cancer Risk Consumption Value Market Share by Type in 2022
 - 1.3.3 Breast Cancer Risk Genetic Testing
 - 1.3.4 Stomach Cancer Risk Gene Testing
 - 1.3.5 Rectal Cancer Risk Genetic Testing
 - 1.3.6 Others
- 1.4 Global Genetic Testing for Cancer Risk Market by Application
- 1.4.1 Overview: Global Genetic Testing for Cancer Risk Market Size by Application: 2018 Versus 2022 Versus 2029
 - 1.4.2 Hospital
 - 1.4.3 Clinic
 - 1.4.4 Laboratory
- 1.5 Global Genetic Testing for Cancer Risk Market Size & Forecast
- 1.6 Global Genetic Testing for Cancer Risk Market Size and Forecast by Region
- 1.6.1 Global Genetic Testing for Cancer Risk Market Size by Region: 2018 VS 2022 VS 2029
 - 1.6.2 Global Genetic Testing for Cancer Risk Market Size by Region, (2018-2029)
- 1.6.3 North America Genetic Testing for Cancer Risk Market Size and Prospect (2018-2029)
 - 1.6.4 Europe Genetic Testing for Cancer Risk Market Size and Prospect (2018-2029)
- 1.6.5 Asia-Pacific Genetic Testing for Cancer Risk Market Size and Prospect (2018-2029)
- 1.6.6 South America Genetic Testing for Cancer Risk Market Size and Prospect (2018-2029)
- 1.6.7 Middle East and Africa Genetic Testing for Cancer Risk Market Size and Prospect (2018-2029)

2 COMPANY PROFILES

2.1 Myriad Genetics, Inc.



- 2.1.1 Myriad Genetics, Inc. Details
- 2.1.2 Myriad Genetics, Inc. Major Business
- 2.1.3 Myriad Genetics, Inc. Genetic Testing for Cancer Risk Product and Solutions
- 2.1.4 Myriad Genetics, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
- 2.1.5 Myriad Genetics, Inc. Recent Developments and Future Plans
- 2.2 Invitae Corporation
 - 2.2.1 Invitae Corporation Details
 - 2.2.2 Invitae Corporation Major Business
 - 2.2.3 Invitae Corporation Genetic Testing for Cancer Risk Product and Solutions
- 2.2.4 Invitae Corporation Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
 - 2.2.5 Invitae Corporation Recent Developments and Future Plans
- 2.3 Illumina, Inc.
 - 2.3.1 Illumina, Inc. Details
 - 2.3.2 Illumina, Inc. Major Business
 - 2.3.3 Illumina, Inc. Genetic Testing for Cancer Risk Product and Solutions
- 2.3.4 Illumina, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
 - 2.3.5 Illumina, Inc. Recent Developments and Future Plans
- 2.4 Natera, Inc.
 - 2.4.1 Natera, Inc. Details
 - 2.4.2 Natera, Inc. Major Business
 - 2.4.3 Natera, Inc. Genetic Testing for Cancer Risk Product and Solutions
- 2.4.4 Natera, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
- 2.4.5 Natera, Inc. Recent Developments and Future Plans
- 2.5 Laboratory Corporation of America Holdings
 - 2.5.1 Laboratory Corporation of America Holdings Details
 - 2.5.2 Laboratory Corporation of America Holdings Major Business
- 2.5.3 Laboratory Corporation of America Holdings Genetic Testing for Cancer Risk Product and Solutions
- 2.5.4 Laboratory Corporation of America Holdings Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
- 2.5.5 Laboratory Corporation of America Holdings Recent Developments and Future Plans
- 2.6 F. Hoffmann-La Roche Ltd
- 2.6.1 F. Hoffmann-La Roche Ltd Details
- 2.6.2 F. Hoffmann-La Roche Ltd Major Business



- 2.6.3 F. Hoffmann-La Roche Ltd Genetic Testing for Cancer Risk Product and Solutions
- 2.6.4 F. Hoffmann-La Roche Ltd Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
 - 2.6.5 F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
- 2.7 Quest Diagnostics Incorporated
 - 2.7.1 Quest Diagnostics Incorporated Details
 - 2.7.2 Quest Diagnostics Incorporated Major Business
- 2.7.3 Quest Diagnostics Incorporated Genetic Testing for Cancer Risk Product and Solutions
- 2.7.4 Quest Diagnostics Incorporated Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
- 2.7.5 Quest Diagnostics Incorporated Recent Developments and Future Plans2.8 CooperSurgical, Inc.
 - 2.8.1 CooperSurgical, Inc. Details
 - 2.8.2 CooperSurgical, Inc. Major Business
 - 2.8.3 CooperSurgical, Inc. Genetic Testing for Cancer Risk Product and Solutions
- 2.8.4 CooperSurgical, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
 - 2.8.5 CooperSurgical, Inc. Recent Developments and Future Plans
- 2.9 Agilent Technologies, Inc.
 - 2.9.1 Agilent Technologies, Inc. Details
 - 2.9.2 Agilent Technologies, Inc. Major Business
- 2.9.3 Agilent Technologies, Inc. Genetic Testing for Cancer Risk Product and Solutions
- 2.9.4 Agilent Technologies, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
 - 2.9.5 Agilent Technologies, Inc. Recent Developments and Future Plans
- 2.10 Thermo Fisher Scientific, Inc.
 - 2.10.1 Thermo Fisher Scientific, Inc. Details
 - 2.10.2 Thermo Fisher Scientific, Inc. Major Business
- 2.10.3 Thermo Fisher Scientific, Inc. Genetic Testing for Cancer Risk Product and Solutions
- 2.10.4 Thermo Fisher Scientific, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
 - 2.10.5 Thermo Fisher Scientific, Inc. Recent Developments and Future Plans
- 2.11 Twist Bioscience
 - 2.11.1 Twist Bioscience Details
 - 2.11.2 Twist Bioscience Major Business



- 2.11.3 Twist Bioscience Genetic Testing for Cancer Risk Product and Solutions
- 2.11.4 Twist Bioscience Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
 - 2.11.5 Twist Bioscience Recent Developments and Future Plans
- 2.12 Sophia Genetics
 - 2.12.1 Sophia Genetics Details
 - 2.12.2 Sophia Genetics Major Business
 - 2.12.3 Sophia Genetics Genetic Testing for Cancer Risk Product and Solutions
- 2.12.4 Sophia Genetics Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
- 2.12.5 Sophia Genetics Recent Developments and Future Plans
- 2.13 Fulgent Genetic, Inc.
 - 2.13.1 Fulgent Genetic, Inc. Details
 - 2.13.2 Fulgent Genetic, Inc. Major Business
 - 2.13.3 Fulgent Genetic, Inc. Genetic Testing for Cancer Risk Product and Solutions
- 2.13.4 Fulgent Genetic, Inc. Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
 - 2.13.5 Fulgent Genetic, Inc. Recent Developments and Future Plans
- 2.14 Medgenome
 - 2.14.1 Medgenome Details
 - 2.14.2 Medgenome Major Business
 - 2.14.3 Medgenome Genetic Testing for Cancer Risk Product and Solutions
- 2.14.4 Medgenome Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
 - 2.14.5 Medgenome Recent Developments and Future Plans
- 2.15 CENTOGENE
 - 2.15.1 CENTOGENE Details
 - 2.15.2 CENTOGENE Major Business
 - 2.15.3 CENTOGENE Genetic Testing for Cancer Risk Product and Solutions
- 2.15.4 CENTOGENE Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
 - 2.15.5 CENTOGENE Recent Developments and Future Plans
- 2.16 CeGaT
 - 2.16.1 CeGaT Details
 - 2.16.2 CeGaT Major Business
 - 2.16.3 CeGaT Genetic Testing for Cancer Risk Product and Solutions
- 2.16.4 CeGaT Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
 - 2.16.5 CeGaT Recent Developments and Future Plans



- 2.17 LifeLabs Genetics
 - 2.17.1 LifeLabs Genetics Details
 - 2.17.2 LifeLabs Genetics Major Business
 - 2.17.3 LifeLabs Genetics Genetic Testing for Cancer Risk Product and Solutions
- 2.17.4 LifeLabs Genetics Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
 - 2.17.5 LifeLabs Genetics Recent Developments and Future Plans
- 2.18 Ambry Genetics
 - 2.18.1 Ambry Genetics Details
 - 2.18.2 Ambry Genetics Major Business
 - 2.18.3 Ambry Genetics Genetic Testing for Cancer Risk Product and Solutions
- 2.18.4 Ambry Genetics Genetic Testing for Cancer Risk Revenue, Gross Margin and Market Share (2018-2023)
 - 2.18.5 Ambry Genetics Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

- 3.1 Global Genetic Testing for Cancer Risk Revenue and Share by Players (2018-2023)
- 3.2 Market Share Analysis (2022)
 - 3.2.1 Market Share of Genetic Testing for Cancer Risk by Company Revenue
 - 3.2.2 Top 3 Genetic Testing for Cancer Risk Players Market Share in 2022
 - 3.2.3 Top 6 Genetic Testing for Cancer Risk Players Market Share in 2022
- 3.3 Genetic Testing for Cancer Risk Market: Overall Company Footprint Analysis
 - 3.3.1 Genetic Testing for Cancer Risk Market: Region Footprint
 - 3.3.2 Genetic Testing for Cancer Risk Market: Company Product Type Footprint
 - 3.3.3 Genetic Testing for Cancer Risk Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

- 4.1 Global Genetic Testing for Cancer Risk Consumption Value and Market Share by Type (2018-2023)
- 4.2 Global Genetic Testing for Cancer Risk Market Forecast by Type (2024-2029)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Genetic Testing for Cancer Risk Consumption Value Market Share by Application (2018-2023)



5.2 Global Genetic Testing for Cancer Risk Market Forecast by Application (2024-2029)

6 NORTH AMERICA

- 6.1 North America Genetic Testing for Cancer Risk Consumption Value by Type (2018-2029)
- 6.2 North America Genetic Testing for Cancer Risk Consumption Value by Application (2018-2029)
- 6.3 North America Genetic Testing for Cancer Risk Market Size by Country
- 6.3.1 North America Genetic Testing for Cancer Risk Consumption Value by Country (2018-2029)
- 6.3.2 United States Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)
 - 6.3.3 Canada Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)
 - 6.3.4 Mexico Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)

7 EUROPE

- 7.1 Europe Genetic Testing for Cancer Risk Consumption Value by Type (2018-2029)
- 7.2 Europe Genetic Testing for Cancer Risk Consumption Value by Application (2018-2029)
- 7.3 Europe Genetic Testing for Cancer Risk Market Size by Country
- 7.3.1 Europe Genetic Testing for Cancer Risk Consumption Value by Country (2018-2029)
- 7.3.2 Germany Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)
- 7.3.3 France Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)
- 7.3.4 United Kingdom Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)
- 7.3.5 Russia Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)
- 7.3.6 Italy Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)

8 ASIA-PACIFIC

- 8.1 Asia-Pacific Genetic Testing for Cancer Risk Consumption Value by Type (2018-2029)
- 8.2 Asia-Pacific Genetic Testing for Cancer Risk Consumption Value by Application (2018-2029)
- 8.3 Asia-Pacific Genetic Testing for Cancer Risk Market Size by Region



- 8.3.1 Asia-Pacific Genetic Testing for Cancer Risk Consumption Value by Region (2018-2029)
- 8.3.2 China Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)
- 8.3.3 Japan Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)
- 8.3.4 South Korea Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)
- 8.3.5 India Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)
- 8.3.6 Southeast Asia Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)
- 8.3.7 Australia Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)

9 SOUTH AMERICA

- 9.1 South America Genetic Testing for Cancer Risk Consumption Value by Type (2018-2029)
- 9.2 South America Genetic Testing for Cancer Risk Consumption Value by Application (2018-2029)
- 9.3 South America Genetic Testing for Cancer Risk Market Size by Country
- 9.3.1 South America Genetic Testing for Cancer Risk Consumption Value by Country (2018-2029)
 - 9.3.2 Brazil Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)
- 9.3.3 Argentina Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)

10 MIDDLE EAST & AFRICA

- 10.1 Middle East & Africa Genetic Testing for Cancer Risk Consumption Value by Type (2018-2029)
- 10.2 Middle East & Africa Genetic Testing for Cancer Risk Consumption Value by Application (2018-2029)
- 10.3 Middle East & Africa Genetic Testing for Cancer Risk Market Size by Country 10.3.1 Middle East & Africa Genetic Testing for Cancer Risk Consumption Value by Country (2018-2029)
 - 10.3.2 Turkey Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)
- 10.3.3 Saudi Arabia Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)
 - 10.3.4 UAE Genetic Testing for Cancer Risk Market Size and Forecast (2018-2029)

11 MARKET DYNAMICS



- 11.1 Genetic Testing for Cancer Risk Market Drivers
- 11.2 Genetic Testing for Cancer Risk Market Restraints
- 11.3 Genetic Testing for Cancer Risk Trends Analysis
- 11.4 Porters Five Forces Analysis
 - 11.4.1 Threat of New Entrants
 - 11.4.2 Bargaining Power of Suppliers
 - 11.4.3 Bargaining Power of Buyers
 - 11.4.4 Threat of Substitutes
 - 11.4.5 Competitive Rivalry
- 11.5 Influence of COVID-19 and Russia-Ukraine War
 - 11.5.1 Influence of COVID-19
 - 11.5.2 Influence of Russia-Ukraine War

12 INDUSTRY CHAIN ANALYSIS

- 12.1 Genetic Testing for Cancer Risk Industry Chain
- 12.2 Genetic Testing for Cancer Risk Upstream Analysis
- 12.3 Genetic Testing for Cancer Risk Midstream Analysis
- 12.4 Genetic Testing for Cancer Risk Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

- 14.1 Methodology
- 14.2 Research Process and Data Source
- 14.3 Disclaimer



List Of Tables

LIST OF TABLES

- Table 1. Global Genetic Testing for Cancer Risk Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Table 2. Global Genetic Testing for Cancer Risk Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
- Table 3. Global Genetic Testing for Cancer Risk Consumption Value by Region (2018-2023) & (USD Million)
- Table 4. Global Genetic Testing for Cancer Risk Consumption Value by Region (2024-2029) & (USD Million)
- Table 5. Myriad Genetics, Inc. Company Information, Head Office, and Major Competitors
- Table 6. Myriad Genetics, Inc. Major Business
- Table 7. Myriad Genetics, Inc. Genetic Testing for Cancer Risk Product and Solutions
- Table 8. Myriad Genetics, Inc. Genetic Testing for Cancer Risk Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 9. Myriad Genetics, Inc. Recent Developments and Future Plans
- Table 10. Invitae Corporation Company Information, Head Office, and Major Competitors
- Table 11. Invitae Corporation Major Business
- Table 12. Invitae Corporation Genetic Testing for Cancer Risk Product and Solutions
- Table 13. Invitae Corporation Genetic Testing for Cancer Risk Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 14. Invitae Corporation Recent Developments and Future Plans
- Table 15. Illumina, Inc. Company Information, Head Office, and Major Competitors
- Table 16. Illumina, Inc. Major Business
- Table 17. Illumina, Inc. Genetic Testing for Cancer Risk Product and Solutions
- Table 18. Illumina, Inc. Genetic Testing for Cancer Risk Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 19. Illumina, Inc. Recent Developments and Future Plans
- Table 20. Natera, Inc. Company Information, Head Office, and Major Competitors
- Table 21. Natera, Inc. Major Business
- Table 22. Natera, Inc. Genetic Testing for Cancer Risk Product and Solutions
- Table 23. Natera, Inc. Genetic Testing for Cancer Risk Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 24. Natera, Inc. Recent Developments and Future Plans
- Table 25. Laboratory Corporation of America Holdings Company Information, Head



- Office, and Major Competitors
- Table 26. Laboratory Corporation of America Holdings Major Business
- Table 27. Laboratory Corporation of America Holdings Genetic Testing for Cancer Risk Product and Solutions
- Table 28. Laboratory Corporation of America Holdings Genetic Testing for Cancer Risk Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 29. Laboratory Corporation of America Holdings Recent Developments and Future Plans
- Table 30. F. Hoffmann-La Roche Ltd Company Information, Head Office, and Major Competitors
- Table 31. F. Hoffmann-La Roche Ltd Major Business
- Table 32. F. Hoffmann-La Roche Ltd Genetic Testing for Cancer Risk Product and Solutions
- Table 33. F. Hoffmann-La Roche Ltd Genetic Testing for Cancer Risk Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 34. F. Hoffmann-La Roche Ltd Recent Developments and Future Plans
- Table 35. Quest Diagnostics Incorporated Company Information, Head Office, and Major Competitors
- Table 36. Quest Diagnostics Incorporated Major Business
- Table 37. Quest Diagnostics Incorporated Genetic Testing for Cancer Risk Product and Solutions
- Table 38. Quest Diagnostics Incorporated Genetic Testing for Cancer Risk Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 39. Quest Diagnostics Incorporated Recent Developments and Future Plans
- Table 40. CooperSurgical, Inc. Company Information, Head Office, and Major Competitors
- Table 41. CooperSurgical, Inc. Major Business
- Table 42. CooperSurgical, Inc. Genetic Testing for Cancer Risk Product and Solutions
- Table 43. CooperSurgical, Inc. Genetic Testing for Cancer Risk Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 44. CooperSurgical, Inc. Recent Developments and Future Plans
- Table 45. Agilent Technologies, Inc. Company Information, Head Office, and Major Competitors
- Table 46. Agilent Technologies, Inc. Major Business
- Table 47. Agilent Technologies, Inc. Genetic Testing for Cancer Risk Product and Solutions
- Table 48. Agilent Technologies, Inc. Genetic Testing for Cancer Risk Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 49. Agilent Technologies, Inc. Recent Developments and Future Plans



- Table 50. Thermo Fisher Scientific, Inc. Company Information, Head Office, and Major Competitors
- Table 51. Thermo Fisher Scientific, Inc. Major Business
- Table 52. Thermo Fisher Scientific, Inc. Genetic Testing for Cancer Risk Product and Solutions
- Table 53. Thermo Fisher Scientific, Inc. Genetic Testing for Cancer Risk Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 54. Thermo Fisher Scientific, Inc. Recent Developments and Future Plans
- Table 55. Twist Bioscience Company Information, Head Office, and Major Competitors
- Table 56. Twist Bioscience Major Business
- Table 57. Twist Bioscience Genetic Testing for Cancer Risk Product and Solutions
- Table 58. Twist Bioscience Genetic Testing for Cancer Risk Revenue (USD Million),
- Gross Margin and Market Share (2018-2023)
- Table 59. Twist Bioscience Recent Developments and Future Plans
- Table 60. Sophia Genetics Company Information, Head Office, and Major Competitors
- Table 61. Sophia Genetics Major Business
- Table 62. Sophia Genetics Genetic Testing for Cancer Risk Product and Solutions
- Table 63. Sophia Genetics Genetic Testing for Cancer Risk Revenue (USD Million),
- Gross Margin and Market Share (2018-2023)
- Table 64. Sophia Genetics Recent Developments and Future Plans
- Table 65. Fulgent Genetic, Inc. Company Information, Head Office, and Major Competitors
- Table 66. Fulgent Genetic, Inc. Major Business
- Table 67. Fulgent Genetic, Inc. Genetic Testing for Cancer Risk Product and Solutions
- Table 68. Fulgent Genetic, Inc. Genetic Testing for Cancer Risk Revenue (USD Million),
- Gross Margin and Market Share (2018-2023)
- Table 69. Fulgent Genetic, Inc. Recent Developments and Future Plans
- Table 70. Medgenome Company Information, Head Office, and Major Competitors
- Table 71. Medgenome Major Business
- Table 72. Medgenome Genetic Testing for Cancer Risk Product and Solutions
- Table 73. Medgenome Genetic Testing for Cancer Risk Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 74. Medgenome Recent Developments and Future Plans
- Table 75. CENTOGENE Company Information, Head Office, and Major Competitors
- Table 76. CENTOGENE Major Business
- Table 77. CENTOGENE Genetic Testing for Cancer Risk Product and Solutions
- Table 78. CENTOGENE Genetic Testing for Cancer Risk Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 79. CENTOGENE Recent Developments and Future Plans



- Table 80. CeGaT Company Information, Head Office, and Major Competitors
- Table 81. CeGaT Major Business
- Table 82. CeGaT Genetic Testing for Cancer Risk Product and Solutions
- Table 83. CeGaT Genetic Testing for Cancer Risk Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 84. CeGaT Recent Developments and Future Plans
- Table 85. LifeLabs Genetics Company Information, Head Office, and Major Competitors
- Table 86. LifeLabs Genetics Major Business
- Table 87. LifeLabs Genetics Genetic Testing for Cancer Risk Product and Solutions
- Table 88. LifeLabs Genetics Genetic Testing for Cancer Risk Revenue (USD Million),
- Gross Margin and Market Share (2018-2023)
- Table 89. LifeLabs Genetics Recent Developments and Future Plans
- Table 90. Ambry Genetics Company Information, Head Office, and Major Competitors
- Table 91. Ambry Genetics Major Business
- Table 92. Ambry Genetics Genetic Testing for Cancer Risk Product and Solutions
- Table 93. Ambry Genetics Genetic Testing for Cancer Risk Revenue (USD Million),
- Gross Margin and Market Share (2018-2023)
- Table 94. Ambry Genetics Recent Developments and Future Plans
- Table 95. Global Genetic Testing for Cancer Risk Revenue (USD Million) by Players (2018-2023)
- Table 96. Global Genetic Testing for Cancer Risk Revenue Share by Players (2018-2023)
- Table 97. Breakdown of Genetic Testing for Cancer Risk by Company Type (Tier 1, Tier 2, and Tier 3)
- Table 98. Market Position of Players in Genetic Testing for Cancer Risk, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
- Table 99. Head Office of Key Genetic Testing for Cancer Risk Players
- Table 100. Genetic Testing for Cancer Risk Market: Company Product Type Footprint
- Table 101. Genetic Testing for Cancer Risk Market: Company Product Application Footprint
- Table 102. Genetic Testing for Cancer Risk New Market Entrants and Barriers to Market Entry
- Table 103. Genetic Testing for Cancer Risk Mergers, Acquisition, Agreements, and Collaborations
- Table 104. Global Genetic Testing for Cancer Risk Consumption Value (USD Million) by Type (2018-2023)
- Table 105. Global Genetic Testing for Cancer Risk Consumption Value Share by Type (2018-2023)
- Table 106. Global Genetic Testing for Cancer Risk Consumption Value Forecast by



Type (2024-2029)

Table 107. Global Genetic Testing for Cancer Risk Consumption Value by Application (2018-2023)

Table 108. Global Genetic Testing for Cancer Risk Consumption Value Forecast by Application (2024-2029)

Table 109. North America Genetic Testing for Cancer Risk Consumption Value by Type (2018-2023) & (USD Million)

Table 110. North America Genetic Testing for Cancer Risk Consumption Value by Type (2024-2029) & (USD Million)

Table 111. North America Genetic Testing for Cancer Risk Consumption Value by Application (2018-2023) & (USD Million)

Table 112. North America Genetic Testing for Cancer Risk Consumption Value by Application (2024-2029) & (USD Million)

Table 113. North America Genetic Testing for Cancer Risk Consumption Value by Country (2018-2023) & (USD Million)

Table 114. North America Genetic Testing for Cancer Risk Consumption Value by Country (2024-2029) & (USD Million)

Table 115. Europe Genetic Testing for Cancer Risk Consumption Value by Type (2018-2023) & (USD Million)

Table 116. Europe Genetic Testing for Cancer Risk Consumption Value by Type (2024-2029) & (USD Million)

Table 117. Europe Genetic Testing for Cancer Risk Consumption Value by Application (2018-2023) & (USD Million)

Table 118. Europe Genetic Testing for Cancer Risk Consumption Value by Application (2024-2029) & (USD Million)

Table 119. Europe Genetic Testing for Cancer Risk Consumption Value by Country (2018-2023) & (USD Million)

Table 120. Europe Genetic Testing for Cancer Risk Consumption Value by Country (2024-2029) & (USD Million)

Table 121. Asia-Pacific Genetic Testing for Cancer Risk Consumption Value by Type (2018-2023) & (USD Million)

Table 122. Asia-Pacific Genetic Testing for Cancer Risk Consumption Value by Type (2024-2029) & (USD Million)

Table 123. Asia-Pacific Genetic Testing for Cancer Risk Consumption Value by Application (2018-2023) & (USD Million)

Table 124. Asia-Pacific Genetic Testing for Cancer Risk Consumption Value by Application (2024-2029) & (USD Million)

Table 125. Asia-Pacific Genetic Testing for Cancer Risk Consumption Value by Region (2018-2023) & (USD Million)



Table 126. Asia-Pacific Genetic Testing for Cancer Risk Consumption Value by Region (2024-2029) & (USD Million)

Table 127. South America Genetic Testing for Cancer Risk Consumption Value by Type (2018-2023) & (USD Million)

Table 128. South America Genetic Testing for Cancer Risk Consumption Value by Type (2024-2029) & (USD Million)

Table 129. South America Genetic Testing for Cancer Risk Consumption Value by Application (2018-2023) & (USD Million)

Table 130. South America Genetic Testing for Cancer Risk Consumption Value by Application (2024-2029) & (USD Million)

Table 131. South America Genetic Testing for Cancer Risk Consumption Value by Country (2018-2023) & (USD Million)

Table 132. South America Genetic Testing for Cancer Risk Consumption Value by Country (2024-2029) & (USD Million)

Table 133. Middle East & Africa Genetic Testing for Cancer Risk Consumption Value by Type (2018-2023) & (USD Million)

Table 134. Middle East & Africa Genetic Testing for Cancer Risk Consumption Value by Type (2024-2029) & (USD Million)

Table 135. Middle East & Africa Genetic Testing for Cancer Risk Consumption Value by Application (2018-2023) & (USD Million)

Table 136. Middle East & Africa Genetic Testing for Cancer Risk Consumption Value by Application (2024-2029) & (USD Million)

Table 137. Middle East & Africa Genetic Testing for Cancer Risk Consumption Value by Country (2018-2023) & (USD Million)

Table 138. Middle East & Africa Genetic Testing for Cancer Risk Consumption Value by Country (2024-2029) & (USD Million)

Table 139. Genetic Testing for Cancer Risk Raw Material

Table 140. Key Suppliers of Genetic Testing for Cancer Risk Raw Materials



List Of Figures

LIST OF FIGURES

Figure 1. Genetic Testing for Cancer Risk Picture

Figure 2. Global Genetic Testing for Cancer Risk Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 3. Global Genetic Testing for Cancer Risk Consumption Value Market Share by Type in 2022

Figure 4. Breast Cancer Risk Genetic Testing

Figure 5. Stomach Cancer Risk Gene Testing

Figure 6. Rectal Cancer Risk Genetic Testing

Figure 7. Others

Figure 8. Global Genetic Testing for Cancer Risk Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 9. Genetic Testing for Cancer Risk Consumption Value Market Share by Application in 2022

Figure 10. Hospital Picture

Figure 11. Clinic Picture

Figure 12. Laboratory Picture

Figure 13. Global Genetic Testing for Cancer Risk Consumption Value, (USD Million): 2018 & 2022 & 2029

Figure 14. Global Genetic Testing for Cancer Risk Consumption Value and Forecast (2018-2029) & (USD Million)

Figure 15. Global Market Genetic Testing for Cancer Risk Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)

Figure 16. Global Genetic Testing for Cancer Risk Consumption Value Market Share by Region (2018-2029)

Figure 17. Global Genetic Testing for Cancer Risk Consumption Value Market Share by Region in 2022

Figure 18. North America Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 20. Asia-Pacific Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 21. South America Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 22. Middle East and Africa Genetic Testing for Cancer Risk Consumption Value



(2018-2029) & (USD Million)

Figure 23. Global Genetic Testing for Cancer Risk Revenue Share by Players in 2022

Figure 24. Genetic Testing for Cancer Risk Market Share by Company Type (Tier 1,

Tier 2 and Tier 3) in 2022

Figure 25. Global Top 3 Players Genetic Testing for Cancer Risk Market Share in 2022

Figure 26. Global Top 6 Players Genetic Testing for Cancer Risk Market Share in 2022

Figure 27. Global Genetic Testing for Cancer Risk Consumption Value Share by Type (2018-2023)

Figure 28. Global Genetic Testing for Cancer Risk Market Share Forecast by Type (2024-2029)

Figure 29. Global Genetic Testing for Cancer Risk Consumption Value Share by Application (2018-2023)

Figure 30. Global Genetic Testing for Cancer Risk Market Share Forecast by Application (2024-2029)

Figure 31. North America Genetic Testing for Cancer Risk Consumption Value Market Share by Type (2018-2029)

Figure 32. North America Genetic Testing for Cancer Risk Consumption Value Market Share by Application (2018-2029)

Figure 33. North America Genetic Testing for Cancer Risk Consumption Value Market Share by Country (2018-2029)

Figure 34. United States Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 35. Canada Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 36. Mexico Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 37. Europe Genetic Testing for Cancer Risk Consumption Value Market Share by Type (2018-2029)

Figure 38. Europe Genetic Testing for Cancer Risk Consumption Value Market Share by Application (2018-2029)

Figure 39. Europe Genetic Testing for Cancer Risk Consumption Value Market Share by Country (2018-2029)

Figure 40. Germany Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 41. France Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 42. United Kingdom Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 43. Russia Genetic Testing for Cancer Risk Consumption Value (2018-2029) &



(USD Million)

Figure 44. Italy Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 45. Asia-Pacific Genetic Testing for Cancer Risk Consumption Value Market Share by Type (2018-2029)

Figure 46. Asia-Pacific Genetic Testing for Cancer Risk Consumption Value Market Share by Application (2018-2029)

Figure 47. Asia-Pacific Genetic Testing for Cancer Risk Consumption Value Market Share by Region (2018-2029)

Figure 48. China Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 49. Japan Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 50. South Korea Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 51. India Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 52. Southeast Asia Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 53. Australia Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 54. South America Genetic Testing for Cancer Risk Consumption Value Market Share by Type (2018-2029)

Figure 55. South America Genetic Testing for Cancer Risk Consumption Value Market Share by Application (2018-2029)

Figure 56. South America Genetic Testing for Cancer Risk Consumption Value Market Share by Country (2018-2029)

Figure 57. Brazil Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 58. Argentina Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 59. Middle East and Africa Genetic Testing for Cancer Risk Consumption Value Market Share by Type (2018-2029)

Figure 60. Middle East and Africa Genetic Testing for Cancer Risk Consumption Value Market Share by Application (2018-2029)

Figure 61. Middle East and Africa Genetic Testing for Cancer Risk Consumption Value Market Share by Country (2018-2029)

Figure 62. Turkey Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)



Figure 63. Saudi Arabia Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 64. UAE Genetic Testing for Cancer Risk Consumption Value (2018-2029) & (USD Million)

Figure 65. Genetic Testing for Cancer Risk Market Drivers

Figure 66. Genetic Testing for Cancer Risk Market Restraints

Figure 67. Genetic Testing for Cancer Risk Market Trends

Figure 68. Porters Five Forces Analysis

Figure 69. Manufacturing Cost Structure Analysis of Genetic Testing for Cancer Risk in 2022

Figure 70. Manufacturing Process Analysis of Genetic Testing for Cancer Risk

Figure 71. Genetic Testing for Cancer Risk Industrial Chain

Figure 72. Methodology

Figure 73. Research Process and Data Source



I would like to order

Product name: Global Genetic Testing for Cancer Risk Market 2023 by Company, Regions, Type and

Application, Forecast to 2029

Product link: https://marketpublishers.com/r/G1A97A8C4A17EN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G1A97A8C4A17EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

